Developer docs
API playgroundTry for free, no card

Search company profiles

4D Molecular Therapeutics

Full company profile

uuid00002u4

Namestring
4D Molecular Therapeutics
Legal namestring
4D Molecular Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2013
Descriptiontext

4D Molecular Therapeutics (NASDAQ: FDMT) is a clinical-stage biotechnology company founded in 2013 and headquartered in Emeryville, California, that designs, develops, and intends to commercialize AAV-based gene therapies for large-market diseases with significant unmet need, primarily in ophthalmology and pulmonology. The company's foundation is its proprietary Therapeutic Vector Evolution platform, which uses directed evolution to invent customized viral vectors with superior tissue targeting, lower dose requirements, and resistance to pre-existing human antibodies compared to conventional AAV; this platform has produced two flagship vectors, R100 (designed for routine low-dose intravitreal delivery to the retina) and A101 (designed for efficient aerosol delivery throughout the lung airway).

The clinical pipeline is anchored by 4D-150, an intravitreal gene therapy expressing two anti-VEGF transgenes for wet age-related macular degeneration and diabetic macular edema, which is being evaluated in the 4FRONT-1 and 4FRONT-2 Phase 3 trials and showed up to a 92% reduction in anti-VEGF injection burden in earlier data. 4D-710 is a mutation-agnostic aerosolized CFTR gene therapy for cystic fibrosis lung disease in Phase 2 with positive interim Phase 1 data; 4D-310 targets Fabry disease cardiomyopathy in Phase 1/2; and preclinical assets 4D-175 (geographic atrophy) and 4D-725 (alpha-1 antitrypsin deficiency lung disease) extend the franchise across the same vectors.

The business model is currently pre-commercial: revenue consists of partnership and licensing income rather than product sales. The company has executed a $85 million upfront (plus up to $336 million in milestones) Asia-Pacific license to Otsuka Pharmaceutical for 4D-150, a separate up-to-$962 million Astellas license for a rare ophthalmology vector, and a $11 million grant plus Joint Steering Committee partnership with the Cystic Fibrosis Foundation supporting 4D-710. Future revenue is expected to shift toward specialty pharmaceutical distribution of gene therapy products priced in the $60,000–$350,000 per-patient range, distributed via specialty pharmacies, hospital systems, and specialty distributors, complemented by regional partnerships such as Otsuka for Asia-Pacific markets.

Short descriptiontext

4D Molecular Therapeutics (NASDAQ: FDMT) is a clinical-stage biotechnology company that designs and develops customized AAV-based gene therapies for large-market retinal and pulmonary diseases using its proprietary Therapeutic Vector Evolution platform, currently advancing lead candidates 4D-150 and 4D-710 through Phase 3 and Phase 2 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEmeryville, United States
HQ citystring
Emeryville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy products, AAV vector platform, retinal disease therapeutics, cystic fibrosis treatment, ophthalmic gene therapy
Industry4 codes
PRIMARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAHAD
Alpha-1 Antitrypsin (AAT) Therapies
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy / Genetic Medicines
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Product Sales
TypeOne Time License
Description

Pre-commercial company developing gene therapies. Primary revenue will come from commercializing lead product 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis. As a late-stage biotech, revenue model will shift from partnership/milestone payments to product sales upon regulatory approval.

4dmoleculartherapeutics.com
2Partnership & Licensing Revenue
TypeLicensing Royalties
Description

Strategic licensing deals including $85M upfront from Otsuka for Asia-Pacific rights to 4D-150, with potential milestone payments up to $336M. Includes upfront payments, development milestones, regulatory milestones, and sales royalties.

fiercebiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company that designs, develops, and commercializes AAV-based gene therapy products using its proprietary Therapeutic Vector Evolution platform. The company's pipeline includes 4D-150 for wet AMD and diabetic macular edema (Phase 3), 4D-710 for cystic fibrosis lung disease (Phase 2), 4D-310 for Fabry disease cardiomyopathy (Phase 1/2), and preclinical candidates 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin lung disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 92% reduction in anti-VEGF injection burden in wet AMD patients
+3 more records
Product overview1 text field

4D Molecular Therapeutics is a clinical-stage genetic medicines company developing a diversified pipeline of AAV-based gene therapies using its proprietary Therapeutic Vector Evolution Platform. The company's clinical-stage products include 4D-150 (wet AMD and DME, Phase 3), 4D-710 (cystic fibrosis, Phase 2), and 4D-310 (Fabry disease, Phase 1/2). Preclinical candidates include 4D-175 for geographic atrophy and 4D-725 for A1AT lung disease. The platform enables invention of customized vectors (R100 for retina, A101 for lung) that overcome limitations of conventional AAV vectors through directed evolution.

Product and service5 records
14D-150
CategoryOphthalmology - Retinal Disease Gene Therapy
Description

AAV-based gene therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Delivered via intravitreal injection, designed to provide continuous expression of two anti-VEGF transgenes from retinal cells for durable suppression of VEGF family members.

24D-710
CategoryPulmonology - Cystic Fibrosis Gene Therapy
Description

Investigational genetic medicine using A101 vector for cystic fibrosis lung disease. Delivered via aerosol, designed for single-dose delivery of corrective CFTRΔR transgene throughout airways and alveoli for mutation-agnostic disease-modifying benefit.

34D-175
CategoryOphthalmology - Geographic Atrophy Gene Therapy
Description

AAV-based intravitreal gene therapy for geographic atrophy. Combines R100 vector with sCFH transgene encoding shortened complement factor H to restore complement regulation and slow disease progression.

44D-725
CategoryPulmonology - A1AT Lung Disease Gene Therapy
Description

Investigational genetic medicine candidate using A101 vector for alpha-1 antitrypsin (A1AT) lung disease. Designed for single-dose aerosol treatment, currently in preclinical development.

54D-310
CategoryCardiology - Fabry Disease Gene Therapy
Description

Gene therapy candidate for Fabry disease cardiomyopathy. Uses AAV vector to deliver functional GLA gene for treatment of Fabry disease, currently in Phase 1/2 clinical trials.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-31
Description

Exclusive license agreement for development and commercialization of 4D-150 for retinal vascular diseases in Asia-Pacific region including Japan, South Korea, Taiwan, Australia, and New Zealand. 4DMT received $85 million upfront payment with potential milestone payments up to $336 million plus double-digit royalties. Otsuka handles development, regulatory, and commercial activities in the region.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-03
Description

Partnership to develop genetic medicines for CNS diseases using combined technologies.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-07-10
Description

Licensing agreement for 4DMT's viral vector for rare ophthalmology gene therapy. Deal valued at up to $962 million including upfront, development, and commercial milestones plus royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage gene therapy company (Vyjuvek) with a redosable HSV-based platform and a pipeline targeting rare diseases. Comparable in being a genetic medicines company with rare disease focus and in-house manufacturing.

TypeDirect peer
Description

Clinical-stage gene therapy company with programs in ophthalmology (AAV for inherited retinal diseases) and rare pulmonary/CF indications. Comparable diversified AAV gene therapy pipeline with in-house manufacturing.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for rare diseases including Huntington's disease and hemophilia B. Comparable business model as a clinical-to-commercial gene therapy developer.

TypeDirect peer
Description

Clinical-stage gene therapy company with an AAV gene delivery platform (NAV Technology) developing therapies for retinal diseases (wet AMD, DME) and rare diseases including CF. Closely comparable technology platform and pipeline overlap.

TypeBroad incumbent
Description

Established rare disease biopharmaceutical company with multiple approved enzyme replacement and gene therapy products (e.g., Roctavian for hemophilia A AAV gene therapy). Comparable as a broad rare disease player with gene therapy expertise and commercial infrastructure.

TypeEmerging player
Description

Clinical-stage gene editing company developing CRISPR-based therapies, with ophthalmology and rare disease focus (e.g., EDIT-101 for LCA10). Comparable as a clinical-stage genetic medicines company in ophthalmology.

TypeEmerging player
Description

Emerging gene therapy company focused on ophthalmic diseases, developing AAV-based therapies for inherited retinal diseases and wet AMD. Direct emerging competitor in retinal gene therapy space.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases, including wet AMD (ADVM-022/Ixo-vec) and other retinal indications. Direct competitor to 4DMT in intravitreal AAV gene therapy for wet AMD.

TypeBroad incumbent
Description

Large pharmaceutical company with an active gene therapy portfolio (Beqvez for hemophilia B; prior 4DMT investor via Pfizer Ventures). Represents the strategic pharma landscape that licenses or competes with 4DMT in AAV gene therapy.

TypeBroad incumbent
Description

Global pharmaceutical company with a gene therapy center of excellence (formerly Audentes Therapeutics). Existing 4DMT licensing partner for rare ophthalmology AAV vector (up to $962M deal), demonstrating comparable interest in AAV gene therapy for ophthalmology and rare diseases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4D Molecular Therapeutics

Gene Therapy / Genetic Medicines4dmoleculartherapeutics.com

4D Molecular Therapeutics (NASDAQ: FDMT) is a clinical-stage biotechnology company that designs and develops customized AAV-based gene therapies for large-market retinal and pulmonary diseases using its proprietary Therapeutic Vector Evolution platform, currently advancing lead candidates 4D-150 and 4D-710 through Phase 3 and Phase 2 trials.

What 4D Molecular Therapeutics does

4D Molecular Therapeutics (NASDAQ: FDMT) is a clinical-stage biotechnology company founded in 2013 and headquartered in Emeryville, California, that designs, develops, and intends to commercialize AAV-based gene therapies for large-market diseases with significant unmet need, primarily in ophthalmology and pulmonology. The company's foundation is its proprietary Therapeutic Vector Evolution platform, which uses directed evolution to invent customized viral vectors with superior tissue targeting, lower dose requirements, and resistance to pre-existing human antibodies compared to conventional AAV; this platform has produced two flagship vectors, R100 (designed for routine low-dose intravitreal delivery to the retina) and A101 (designed for efficient aerosol delivery throughout the lung airway).

The clinical pipeline is anchored by 4D-150, an intravitreal gene therapy expressing two anti-VEGF transgenes for wet age-related macular degeneration and diabetic macular edema, which is being evaluated in the 4FRONT-1 and 4FRONT-2 Phase 3 trials and showed up to a 92% reduction in anti-VEGF injection burden in earlier data. 4D-710 is a mutation-agnostic aerosolized CFTR gene therapy for cystic fibrosis lung disease in Phase 2 with positive interim Phase 1 data; 4D-310 targets Fabry disease cardiomyopathy in Phase 1/2; and preclinical assets 4D-175 (geographic atrophy) and 4D-725 (alpha-1 antitrypsin deficiency lung disease) extend the franchise across the same vectors.

The business model is currently pre-commercial: revenue consists of partnership and licensing income rather than product sales. The company has executed a $85 million upfront (plus up to $336 million in milestones) Asia-Pacific license to Otsuka Pharmaceutical for 4D-150, a separate up-to-$962 million Astellas license for a rare ophthalmology vector, and a $11 million grant plus Joint Steering Committee partnership with the Cystic Fibrosis Foundation supporting 4D-710. Future revenue is expected to shift toward specialty pharmaceutical distribution of gene therapy products priced in the $60,000–$350,000 per-patient range, distributed via specialty pharmacies, hospital systems, and specialty distributors, complemented by regional partnerships such as Otsuka for Asia-Pacific markets.

4D Molecular Therapeutics firmographics

Firmographics
Name
4D Molecular Therapeutics
Legal name
4D Molecular Therapeutics, Inc.
Website
https://4dmoleculartherapeutics.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
4D Molecular Therapeutics (NASDAQ: FDMT) is a clinical-stage biotechnology company that designs and develops customized AAV-based gene therapies for large-market retinal and pulmonary diseases using its proprietary Therapeutic Vector Evolution platform, currently advancing lead candidates 4D-150 and 4D-710 through Phase 3 and Phase 2 trials.
Ownership category
akta.pro rank

4D Molecular Therapeutics industry classification

Industry
Product category
Gene Therapy / Genetic Medicines
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAHAD
Alpha-1 Antitrypsin (AAT) Therapies

Keywords

  • Gene therapy products
  • AAV vector platform
  • Retinal disease therapeutics
  • Cystic fibrosis treatment
  • Ophthalmic gene therapy

Where 4D Molecular Therapeutics is headquartered

Location

Headquarters

HQ city
Emeryville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

4D Molecular Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Gene Therapy Product Sales: Pre-commercial company developing gene therapies. Primary revenue will come from commercializing lead product 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis. As a late-stage biotech, revenue model will shift from partnership/milestone payments to product sales upon regulatory approval.
  2. Partnership & Licensing Revenue: Strategic licensing deals including $85M upfront from Otsuka for Asia-Pacific rights to 4D-150, with potential milestone payments up to $336M. Includes upfront payments, development milestones, regulatory milestones, and sales royalties.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

4D Molecular Therapeutics product offering

Product offering

Core offering

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company that designs, develops, and commercializes AAV-based gene therapy products using its proprietary Therapeutic Vector Evolution platform. The company's pipeline includes 4D-150 for wet AMD and diabetic macular edema (Phase 3), 4D-710 for cystic fibrosis lung disease (Phase 2), 4D-310 for Fabry disease cardiomyopathy (Phase 1/2), and preclinical candidates 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin lung disease.

Product overview

4D Molecular Therapeutics is a clinical-stage genetic medicines company developing a diversified pipeline of AAV-based gene therapies using its proprietary Therapeutic Vector Evolution Platform. The company's clinical-stage products include 4D-150 (wet AMD and DME, Phase 3), 4D-710 (cystic fibrosis, Phase 2), and 4D-310 (Fabry disease, Phase 1/2). Preclinical candidates include 4D-175 for geographic atrophy and 4D-725 for A1AT lung disease. The platform enables invention of customized vectors (R100 for retina, A101 for lung) that overcome limitations of conventional AAV vectors through directed evolution.

Differentiator

Problem solved

Functional benefit

Products and services

  • 4D-150 AAV-based gene therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Delivered via intravitreal injection, designed to provide continuous expression of two anti-VEGF transgenes from retinal cells for durable suppression of VEGF family members.
  • 4D-710 Investigational genetic medicine using A101 vector for cystic fibrosis lung disease. Delivered via aerosol, designed for single-dose delivery of corrective CFTRΔR transgene throughout airways and alveoli for mutation-agnostic disease-modifying benefit.
  • 4D-175 AAV-based intravitreal gene therapy for geographic atrophy. Combines R100 vector with sCFH transgene encoding shortened complement factor H to restore complement regulation and slow disease progression.
  • 4D-725 Investigational genetic medicine candidate using A101 vector for alpha-1 antitrypsin (A1AT) lung disease. Designed for single-dose aerosol treatment, currently in preclinical development.
  • 4D-310 Gene therapy candidate for Fabry disease cardiomyopathy. Uses AAV vector to deliver functional GLA gene for treatment of Fabry disease, currently in Phase 1/2 clinical trials.

Quantifiable outcome

  • 92% reduction in anti-VEGF injection burden in wet AMD patients
  • +3 more outcomes

Companies that use 4D Molecular Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

4D Molecular Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

4D Molecular Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Otsuka Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 31 October 2025Exclusive license agreement for development and commercialization of 4D-150 for retinal vascular diseases in Asia-Pacific region including Japan, South Korea, Taiwan, Australia, and New Zealand. 4DMT received $85 million upfront payment with potential milestone payments up to $336 million plus double-digit royalties. Otsuka handles development, regulatory, and commercial activities in the region.
  • Arbor BiotechnologiesminorStrategic or Co-development Partner · 3 January 2024Partnership to develop genetic medicines for CNS diseases using combined technologies.
  • Astellas PharmaminorOEM/ Whitelabel/ Licensing Partner · 10 July 2023Licensing agreement for 4DMT's viral vector for rare ophthalmology gene therapy. Deal valued at up to $962 million including upfront, development, and commercial milestones plus royalties.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

4D Molecular Therapeutics competitors and assessment

Company assessment

Direct peers

  • Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek) with a redosable HSV-based platform and a pipeline targeting rare diseases. Comparable in being a genetic medicines company with rare disease focus and in-house manufacturing.
  • MeiraGTx Holdings: Clinical-stage gene therapy company with programs in ophthalmology (AAV for inherited retinal diseases) and rare pulmonary/CF indications. Comparable diversified AAV gene therapy pipeline with in-house manufacturing.
  • uniQure N.V. Clinical-stage gene therapy company developing AAV-based therapies for rare diseases including Huntington's disease and hemophilia B. Comparable business model as a clinical-to-commercial gene therapy developer.
  • REGENXBIO: Clinical-stage gene therapy company with an AAV gene delivery platform (NAV Technology) developing therapies for retinal diseases (wet AMD, DME) and rare diseases including CF. Closely comparable technology platform and pipeline overlap.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases, including wet AMD (ADVM-022/Ixo-vec) and other retinal indications. Direct competitor to 4DMT in intravitreal AAV gene therapy for wet AMD.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease biopharmaceutical company with multiple approved enzyme replacement and gene therapy products (e.g., Roctavian for hemophilia A AAV gene therapy). Comparable as a broad rare disease player with gene therapy expertise and commercial infrastructure.
  • Pfizer (Gene Therapy Division): Large pharmaceutical company with an active gene therapy portfolio (Beqvez for hemophilia B; prior 4DMT investor via Pfizer Ventures). Represents the strategic pharma landscape that licenses or competes with 4DMT in AAV gene therapy.
  • Astellas Pharma (Astellas Gene Therapies): Global pharmaceutical company with a gene therapy center of excellence (formerly Audentes Therapeutics). Existing 4DMT licensing partner for rare ophthalmology AAV vector (up to $962M deal), demonstrating comparable interest in AAV gene therapy for ophthalmology and rare diseases.

Emerging players

  • Editas Medicine: Clinical-stage gene editing company developing CRISPR-based therapies, with ophthalmology and rare disease focus (e.g., EDIT-101 for LCA10). Comparable as a clinical-stage genetic medicines company in ophthalmology.
  • Beacon Therapeutics: Emerging gene therapy company focused on ophthalmic diseases, developing AAV-based therapies for inherited retinal diseases and wet AMD. Direct emerging competitor in retinal gene therapy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

4D Molecular Therapeutics social profiles

Digital presence

4D Molecular Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4D Molecular Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

4D Molecular Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4D Molecular Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4D Molecular Therapeutics

What does 4D Molecular Therapeutics do?

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company that designs, develops, and commercializes AAV-based gene therapy products using its proprietary Therapeutic Vector Evolution platform. The company's pipeline includes 4D-150 for wet AMD and diabetic macular edema (Phase 3), 4D-710 for cystic fibrosis lung disease (Phase 2), 4D-310 for Fabry disease cardiomyopathy (Phase 1/2), and preclinical candidates 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin lung disease.

Is 4D Molecular Therapeutics a public or private company?

4D Molecular Therapeutics is a public company. It is classified as public and is currently operating.

When was 4D Molecular Therapeutics founded?

4D Molecular Therapeutics was founded in 2013. It employs 101 to 250 people.

Where is 4D Molecular Therapeutics based?

4D Molecular Therapeutics is headquartered in Emeryville, United States, in the North America region.

How does 4D Molecular Therapeutics make money?

Two revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are partnership & Licensing Revenue.

Who are 4D Molecular Therapeutics's main competitors?

Direct peers on record are Krystal Biotech, MeiraGTx Holdings, uniQure N.V., REGENXBIO and Adverum Biotechnologies. Broad incumbents are BioMarin Pharmaceutical, Pfizer (Gene Therapy Division) and Astellas Pharma (Astellas Gene Therapies). Emerging players are Editas Medicine and Beacon Therapeutics.

Does 4D Molecular Therapeutics have an API?

No public API is recorded for 4D Molecular Therapeutics.

What industry is 4D Molecular Therapeutics in?

4D Molecular Therapeutics's product category is Gene Therapy / Genetic Medicines. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies, with a secondary code of HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking Alpha4D Molecular Therapeutics, Inc. (FDMT) Presents at Stifel 2026 Healthcare Conference 2026 Transcript4D Molecular Therapeutics presented at the Stifel 2026 Healthcare Conference, focusing on its lead retina program 4D-150. The company stated 4D-150 has potential to establish a new treatment paradigm for wet age-related macular degeneration, with a single intravitreal dose for lifelong continuous disease control.Stock Titan4D Molecular Therapeutics Grants 21,800 RSUs4D Molecular Therapeutics granted 21,800 restricted stock units to a non-executive employee on November 10, 2026, under its 2025 Employment Inducement Award Plan. The grant was made pursuant to Nasdaq Rule 5635(c)(4) to induce new employment.Stock Titan4D Molecular Therapeutics Q3 earnings: loss widens to $78M4D Molecular Therapeutics reported a Q3 2026 net loss of $78.1 million, widening from $56.9 million in the prior year. Cash and equivalents stood at $375 million as of September 30, 2026, with the company expecting to fund operations into the second half of 2028. The company also completed randomization in its 4FRONT-2 Phase 3 trial for wet AMD.Seeking Alpha4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript4D Molecular Therapeutics presented at the Guggenheim Healthcare Innovation Conference, with CFO Kristian Humer and CCO Chris Simms discussing the company's genetic medicines approach. The company leverages Nobel Prize-winning directed evolution technology to develop vectors that target specific tissues for gene delivery.American Banking and Market News4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Target Price of $30.22Analysts rate 4D Molecular Therapeutics with an average "Moderate Buy" and a $30.22 price target. The stock opened at $12.25, and insiders sold 123,790 shares over three months. Institutional investors own 99.27% of the company.Stock Titan4D Molecular Therapeutics Schedules 7 Conference Talks4D Molecular Therapeutics will present and hold one-on-one meetings at seven investor conferences in November and December 2026. The company's lead product candidate, 4D-150, is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.American Banking and Market NewsContrasting Protalix BioTherapeutics (NYSE:PLX) & 4D Molecular Therapeutics (NASDAQ:FDMT)Protalix BioTherapeutics and 4D Molecular Therapeutics are compared on valuation, profitability, and analyst ratings. Protalix has higher earnings and a stronger consensus rating, with a 363% upside target versus 4D's 154%. Analysts favor Protalix as the more favorable investment.American Banking and Market NewsCritical Contrast: 4D Molecular Therapeutics (NASDAQ:FDMT) versus Oncocyte (NASDAQ:IMDX)A comparison of Oncocyte and 4D Molecular Therapeutics evaluates their financials, analyst ratings, and institutional ownership. 4D Molecular Therapeutics beats Oncocyte on 6 of 11 factors, including lower valuation and higher upside potential. Oncocyte's consensus price target is $10.50, implying 232.28% upside, while 4D's is $28.90, implying 141.64% upside.American Banking and Market News4D Molecular Therapeutics (NASDAQ:FDMT) Earns Buy Rating from HC WainwrightHC Wainwright restated a buy rating on 4D Molecular Therapeutics with a $36 price target, implying 233.33% upside. The stock opened at $10.80, and the company reported a loss of $1.04 per share for the quarter. Analysts have a consensus 'Moderate Buy' rating with an average price target of $28.90.MarketBeat4D Molecular Therapeutics' (FDMT) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a buy rating on 4D Molecular Therapeutics with a $36 price objective, implying 185.26% upside. The stock opened at $12.62, and insiders sold 136,205 shares over three months. Analysts have a Moderate Buy consensus with a $28.90 target.